Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progression

IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety

In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area

Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progression

Astellas Pharma announced the first results from the open-label extension (OLE) trial of the phase 3 GATHER2 study, which showed that monthly treatment with Izervay (avacincaptad pegol intravitreal solution) continued to slow disease progression in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) for up to 3.5 years. The findings, presented during Retina Subspecialty Day at the American Academy of Ophthal…